Showcasing a powerful antioxidant blend for liver detoxification support*
02 Mar 2022
*Advertorial - PAW Hepatoadvanced
Find out how you can better support your liver patients while keeping dosing effortless for clients.
Hepatobiliary disease is an important cause of morbidity and mortality in dogs and cats.1 By virtue of its crucial role in metabolism and detoxification, along with its unique dual blood supply allowing entry of toxins directly from the gastrointestinal tract, the liver is particularly susceptible to damage.2
The healthy liver has an elaborate antioxidant network. Glutathione, the most abundant and important intracellular antioxidant in the body, and vitamin E are both imperative components.2, 3 Indeed, hepatocytes are protected from significant damage primarily due to the liver’s capacity to synthesise glutathione, which effectively eliminates free radicals or reactive oxygen species (ROS).4 However, in liver disease, glutathione production is compromised, consequently leading to oxidative damage.
While the best approach to liver disease is to address the underlying cause, as oxidative stress plays a major pathogenetic role in hepatobiliary disease, antioxidant therapy is of vital importance in supporting acute and chronic liver patients.2, 5
S-adenosylmethionine (SAMe) is an intermediary metabolite that is synthesised from the amino acid methionine.6 SAMe is a glutathione precursor, with oral supplementation proven to replenish hepatic glutathione concentrations in dogs.7 SAMe is also hepatoprotective, immunomodulatory and has some neuroprotective effects.
Another potent antioxidant used in liver disease management is silymarin. Silymarin is the extract from the milk thistle plant (Silybum marianum)and is composed of flavonolignans, of which the most biologically active is silybin.8 Primarily, silymarin acts as an antioxidant by scavenging free radicals and replenishing glutathione concentrations.8, 9 In addition, it has hepatoprotective, anti-inflammatory, antifibrotic and anti-cholestatic properties.9 The poor oral bioavailability of silybin can be overcome through its incorporation in a phosphatidylcholine complex known as a ‘phytosome’, which is proven to significantly enhance bioavailability in dogs and cats compared to standardised milk thistle alone.8
Finally, vitamin E is a lipid-soluble vitamin and powerful endogenous antioxidant. 3, 8 Antioxidant properties aside, vitamin E also aids in preserving hepatocyte integrity, exhibits immunomodulatory effects and acts as an antifibrotic. 10 Moreover, similar to SAMe and silymarin, vitamin E replenishes hepatic glutathione levels.
This unique blend of potent antioxidants is now available in PAW Hepatoadvanced, the newest liver support product to hit the veterinary market. PAW Hepatoadvanced is a chewable fish flavoured tablet for ultimate dosing convenience, designed to provide detoxification support in canine and feline liver disease management. It contains a stable tosylated form of SAMe, silybin in a phosphatidylcholine complex and vitamin E as its key active ingredients and has been specially formulated with delayed release technology, enabling steady absorption over three hours.
Hepatoadvanced can make a difference for your liver patients by enhancing glutathione production, aiding in the protection against medication-induced liver injury, providing support in acute liver toxicities and by supporting brain health in dogs.
For more information on how PAW Hepatoadvanced can help transform the lives of your liver patients, please contact your PAW by Blackmores representative today.
References:
1. Lidbury JA, Suchodolski JS. New advances in the diagnosis of canine and feline liver and pancreatic disease. Vet J. 2016; 215:87-95. doi: 10.1016/j.tvjl.2016.02.010. Epub 2016 Feb 24. PMID: 26951862.
2. Webster CR, Cooper J. Therapeutic use of cytoprotective agents in canine and feline hepatobiliary disease. Vet Clin North Am Small Anim Pract. 2009 May;39(3):631-52. doi: 10.1016/j.cvsm.2009.02.002. PMID: 19524797.
3. Hagen DM et al. Antioxidant supplementation during illness in dogs: effect on oxidative stress and outcome, an exploratory study. J Small An Pract. 2019; 60: 543- 550. doi: 10.1111/jsap.13050
4. Center SA, Warner KL, McCabe J, Foureman P, Hoffmann WE, Erb HN. Evaluation of the influence of S-adenosylmethionine on systemic and hepatic effects of prednisolone in dogs. Am J Vet Res. 2005 Feb;66(2):330-41. doi: 10.2460/ajvr.2005.66.330. PMID: 15757136.
5. Bonagura JD, Twedt DC. (2009). Kirk’s Current Veterinary Therapy XIV. Chapter 128. Saunders- Elsevier. pp. 554- 557
6. Rème CA, Dramard V, Kern L, Hofmans J, Halsberghe C, Mombiela DV. Effect of S-adenosylmethionine tablets on the reduction of age-related mental decline in dogs: a double-blinded, placebo-controlled trial. Vet Ther. 2008 Summer;9(2):69-82. PMID: 18597245.
7. Webster, CRL, Center, SA, Cullen, JM, et al. ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in dogs. J Vet Intern Med. 2019; 33: 1173 - 1200.
8. Fascetti AJ & Delaney SJ. (2012). Applied Veterinary Clinical Nutrition. 1st ed. Wiley- Blackwell. pp. 243
9. Hacket ES, Twedt DC, Gustafson DL. Milk thistle and its derivative compounds: A review of opportunities for the treatment of liver disease. J Vet Intern Med. 2013; 27: 10-16. doi: 10.1111/jvim.12002
10. Nagashimada M, Ota T. Role of Vitamin E in nonalcoholic fatty liver disease. Intern Union of Biochem Mol Biol. 2019; 71(4): 516- 522. doi: 10.1002/iub.1991